Upstream Bio (UPB) Competitors $17.63 -0.11 (-0.62%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$17.62 -0.01 (-0.06%) As of 08/22/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock UPB vs. PTCT, MLTX, PTGX, MIRM, MTSR, SRRK, MENS, APLS, MOR, and AMRXShould you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include PTC Therapeutics (PTCT), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Mirum Pharmaceuticals (MIRM), Metsera (MTSR), Scholar Rock (SRRK), Jyong Biotech (MENS), Apellis Pharmaceuticals (APLS), MorphoSys (MOR), and AMNEAL PHARMACEUTICALS (AMRX). These companies are all part of the "pharmaceutical products" industry. Upstream Bio vs. Its Competitors PTC Therapeutics MoonLake Immunotherapeutics Protagonist Therapeutics Mirum Pharmaceuticals Metsera Scholar Rock Jyong Biotech Apellis Pharmaceuticals MorphoSys AMNEAL PHARMACEUTICALS Upstream Bio (NASDAQ:UPB) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment. Do analysts prefer UPB or PTCT? Upstream Bio currently has a consensus target price of $56.50, indicating a potential upside of 220.48%. PTC Therapeutics has a consensus target price of $69.15, indicating a potential upside of 36.75%. Given Upstream Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Upstream Bio is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.63 Is UPB or PTCT more profitable? PTC Therapeutics has a net margin of 35.65% compared to Upstream Bio's net margin of -3,836.58%. Upstream Bio's return on equity of -35.90% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Upstream Bio-3,836.58% -35.90% -26.26% PTC Therapeutics 35.65%-106.31%30.61% Which has stronger earnings and valuation, UPB or PTCT? Upstream Bio has higher earnings, but lower revenue than PTC Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream Bio$2.37M401.03-$62.81MN/AN/APTC Therapeutics$806.78M4.98-$363.30M$6.977.26 Does the media prefer UPB or PTCT? In the previous week, PTC Therapeutics had 33 more articles in the media than Upstream Bio. MarketBeat recorded 35 mentions for PTC Therapeutics and 2 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.30 beat PTC Therapeutics' score of 0.02 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PTC Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryUpstream Bio and PTC Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Upstream Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPB vs. The Competition Export to ExcelMetricUpstream BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$950.42M$3.13B$5.83B$9.78BDividend YieldN/A2.24%4.40%4.05%P/E RatioN/A7.6222.8124.74Price / Sales401.03396.93473.17122.93Price / CashN/A44.5038.0259.36Price / Book2.338.129.536.60Net Income-$62.81M-$54.72M$3.26B$265.65M7 Day Performance-6.87%2.62%2.14%2.02%1 Month Performance52.91%2.68%2.81%-0.32%1 Year PerformanceN/A10.93%30.70%19.06% Upstream Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPBUpstream Bio2.1039 of 5 stars$17.63-0.6%$56.50+220.5%N/A$950.42M$2.37M0.0038PTCTPTC Therapeutics4.4355 of 5 stars$44.65+3.1%$70.15+57.1%+51.3%$3.55B$806.78M6.401,410Trending NewsAnalyst ForecastAnalyst RevisionMLTXMoonLake Immunotherapeutics1.6279 of 5 stars$54.00+1.2%$74.43+37.8%+15.0%$3.46BN/A-19.422PTGXProtagonist Therapeutics1.8053 of 5 stars$54.00+0.5%$67.20+24.4%+38.7%$3.36B$434.43M77.24120Positive NewsMIRMMirum Pharmaceuticals3.4996 of 5 stars$65.79-0.1%$74.13+12.7%+74.5%$3.30B$336.89M-54.28140News CoveragePositive NewsMTSRMetseraN/A$29.71-1.4%$55.00+85.1%N/A$3.12BN/A0.0081News CoveragePositive NewsSRRKScholar Rock4.5851 of 5 stars$32.05+1.9%$45.14+40.9%+294.8%$3.07B$33.19M-10.97140News CoverageAnalyst ForecastMENSJyong BiotechN/A$40.00-19.3%N/AN/A$3.04BN/A0.0031News CoverageAPLSApellis Pharmaceuticals4.1599 of 5 stars$24.00+0.6%$34.12+42.2%-28.5%$3.03B$781.37M-13.19770News CoverageInsider TradeShort Interest ↑MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsAMRXAMNEAL PHARMACEUTICALS3.3101 of 5 stars$9.03+2.1%$11.60+28.5%+19.1%$2.83B$2.79B903.408,100News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies PTCT Alternatives MLTX Alternatives PTGX Alternatives MIRM Alternatives MTSR Alternatives SRRK Alternatives MENS Alternatives APLS Alternatives MOR Alternatives AMRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPB) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access